Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2024-02-14 4:58 pm Sale | 13G | PROTAGONIST THERAPEUTICS INC C PTGX | CITADEL ADVISORS LLC | 390,512 0.7% | -2,292,302 (-85.44%) | View |
| 2024-02-14 09:31 am Purchase | 13G | PROTAGONIST THERAPEUTICS INC C PTGX | BIOTECHNOLOGY VALUE FUND L P | 5,763,948 9.99% | 738,048 (+14.68%) | View |
| 2024-02-14 07:47 am Purchase | 13G | PROTAGONIST THERAPEUTICS INC C PTGX | RTW INVESTMENTS LP | 5,315,514 9.2% | 1,723,528 (+47.98%) | View |
| 2024-02-14 07:15 am Sale | 13G | PROTAGONIST THERAPEUTICS INC C PTGX | Point72 Asset Management L.P. | 2,613,453 4.5% | -572,624 (-17.97%) | View |
| 2024-02-13 5:12 pm Purchase | 13G | PROTAGONIST THERAPEUTICS INC C PTGX | VANGUARD GROUP INC | 3,153,916 5.47% | 56,202 (+1.81%) | View |
| 2024-02-07 07:41 am Sale | 13G | PROTAGONIST THERAPEUTICS INC C PTGX | ADAGE CAPITAL PARTNERS GP L.L.C. | 1,291,701 2.24% | -1,663,299 (-56.29%) | View |
| 2024-02-02 09:19 am Purchase | 13G | PROTAGONIST THERAPEUTICS INC C PTGX | Farallon Capital Partners L.P. | 5,765,109 9.99% | 710,007 (+14.05%) | View |
| 2024-01-24 2:27 pm Purchase | 13G | PROTAGONIST THERAPEUTICS INC C PTGX | BlackRock Inc. BLK | 5,543,902 9.6% | 1,891,745 (+51.80%) | View |
| 2024-01-23 10:55 am Sale | 13G | PROTAGONIST THERAPEUTICS INC C PTGX | STATE STREET CORP STT | 2,729,929 4.73% | -1,062,997 (-28.03%) | View |
| 2023-12-18 4:15 pm Purchase | 13G | PROTAGONIST THERAPEUTICS INC C PTGX | Point72 Asset Management L.P. | 3,186,077 5.5% | 2,818,071 (+765.77%) | View |
| 2023-04-13 4:30 pm Purchase | 13G | PROTAGONIST THERAPEUTICS INC C PTGX | ADAGE CAPITAL PARTNERS GP L.L.C. | 2,955,000 5.44% | 1,804,955 (+156.95%) | View |
| 2023-03-20 5:04 pm Purchase | 13G | PROTAGONIST THERAPEUTICS INC C PTGX | BIOTECHNOLOGY VALUE FUND L P | 5,025,900 9.6% | 3,775,900 (+302.07%) | View |
| 2023-02-14 4:11 pm Sale | 13G | PROTAGONIST THERAPEUTICS INC C PTGX | Point72 Asset Management L.P. | 368,006 0.7% | -2,052,303 (-84.80%) | View |
| 2023-02-14 10:04 am Purchase | 13G | PROTAGONIST THERAPEUTICS INC C PTGX | RTW INVESTMENTS LP | 3,591,986 7.3% | 992,164 (+38.16%) | View |
| 2023-02-13 6:19 pm Sale | 13G | PROTAGONIST THERAPEUTICS INC C PTGX | BIOTECHNOLOGY VALUE FUND L P | 1,250,000 2.5% | -3,641,945 (-74.45%) | View |
| 2023-02-09 4:54 pm Purchase | 13G | PROTAGONIST THERAPEUTICS INC C PTGX | Farallon Capital Partners L.P. | 5,055,102 9.99% | 5,055,102 (New Position) | View |
| 2023-02-09 11:30 am Purchase | 13G | PROTAGONIST THERAPEUTICS INC C PTGX | VANGUARD GROUP INC | 3,097,714 6.3% | 3,097,714 (New Position) | View |
| 2023-01-31 1:58 pm Purchase | 13G | PROTAGONIST THERAPEUTICS INC C PTGX | BlackRock Inc. BLK | 3,652,157 7.4% | 370,521 (+11.29%) | View |
| 2023-01-11 1:00 pm Unchanged | 13G | PROTAGONIST THERAPEUTICS INC C PTGX | JOHNSON & JOHNSON JNJ | 2,449,183 4.98% | 0 (Unchanged) | View |
| 2023-01-10 08:18 am Sale | 13G | PROTAGONIST THERAPEUTICS INC C PTGX | STATE STREET CORP STT | 3,792,926 7.71% | -2,983,343 (-44.03%) | View |